Investor Presentation First Nine Months of 2022
14
Investor presentation First nine months of 2022
R&D milestones
Project
Diabetes care
FDC Sema
-
OW GIP
Obesity care
CagriSema in T2D
Once weekly oral sema
Insulin Icodec
Higher doses injectable sema
Oral sema (25/50mg)
Rare disease
CagriSema
Oral sema 50 mg
PYY 1875
LA-GDF15
Nedosiran
Mim8
Concizumab
Q3 2022
✓ Phase 2 results
✓ Phase 1 initiation
✓ Phase 3a results
Phase 2 initiation
Q4 2022
Novo NordiskⓇ
Clinical milestones¹
Regulatory milestones¹
H1 2023
Phase 2 results
Submission (US/EU/CN)
Phase 3 results
✓ Phase 3 initiation
Phase 3 results
Phase 1/2 results
✓ Phase 1 results
✓ Submission in PH 1 (US)
✓ Phase 3 treatment²
✓ US/JP submission (HWI)
Phase 3a results (HwoI)
EU submission (HwI)
✓ Phase 2 results
1
Other serious chronic
diseases
Oral PCSK9i
Expected to be published in the given quarter or in the subsequent quarterly company announcement. 2 First patient first visit in Q4 2021, which is solely for baselining purposes;
sema: semaglutide; HwI: Haemophilia with inhibitors; HwoI: Haemophilia without inhibitors, FDC: Fixed dose combination, OW: once weekly; T2DM:Type 2 Diabetes Mellitus; US: United States; EU: European Union; CN: China; JP: JapanView entire presentation